Clinical Trials

As part of the development process, our investigational radioligand products are evaluated in clinical trials to find new and better ways to image and treat disease. These studies are sponsored by Advanced Accelerator Applications (AAA).

Investigational products tested in clinical trials may not be approved by regulatory authorities, or they may be approved for certain indications but being tested to determine if they are useful in other conditions. Patients should discuss their potential participation in such studies with their physician. The table below lists ongoing oncology clinical trials with our investigational drugs.

Please Select Compound
Please select disease state
Study numberStudy name/TitlePhase
NCT04838626
GuideView: Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
III
NCT04838613
GuidePath: Study of Diagnostic Performance of [18F]CTT1057 in BCR (Biochemical Recurrence)
III
NCT04720157
PSMAddition: International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC
III
NCT04712721
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
I
NCT04711135
Netter-P: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
II
NCT04689828
PSMAfore: 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
III
NCT04597411
AcTION: A Phase I Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer and Extensive Skeletal Metastases
I
NCT03972488
Netter-2: Study to evaluate the efficacy and safety of Lutathera in patients with grade 2 and grade 3 advanced GEP-NET
III
NCT03872778
NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB* Lesion Uptake

*Formerly known as NeoBOMB1
I/IIa
NCT03511664
VISION: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
III
NCT03490838
PROter: 177Lu-PSMA-R2 in patients with positive progressive, metastatic, castration resistant prostate cancer
I/II
NCT03490032
PROfind: 68Ga-PSMA-R2 in patients with biochemical relapse and metastatic prostate cancer
I/II
NCT01578239
Netter-1: Study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumors
III